Falls 26% as New Treatment Fails to Get FDA Green Light

finance.yahoo.com/news/ultragenyx-rare-falls-26-treatment-191228393.html

In This Article:
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the stocks drowned heavily. Are you holding any?
Ultragenyx fell by 26.05 percent week-on-week as investor sentiment was largely dragged down by the Food and Drug Administration’s (FDA) rejection of its biologics…

This story appeared on finance.yahoo.com, 2025-07-13 19:12:28.
The Entire Business World on a Single Page. Free to Use →